Common use of PRINCIPLES OF COLLABORATION Clause in Contracts

PRINCIPLES OF COLLABORATION. (1) It is necessary that the COLLABORATION PARTNER complies with each of the follow- ing requirements, otherwise GMC a. has at its sole discretion the right to reject MOUSELINE or b. may not to carry out one or more particular tests. GMC may in exceptional cases agree to some changes of the requirements (for in- stance the number of mice), if it is informed about and has agreed to it before re- ceiving the mice. If GMC accepts a change in its procedure, the COLLABORATION PARTNER accepts that changes may have an impact on the results. However, GMC shall not be obliged to accept the COLLABORATION PARTNER’s request, but may decide to reject it for internal reasons. (2) If GMC rejects the phenotypic analysis because the COLLABORATION PARTNER did not fulfil one or more of the requirements of section 1 (3), the COLLABORATION PARTNER is obliged to reimburse GMC for all incurred expenses in connection with the intended collaboration. (3) The COLLABORATION PARTNER shall deliver the following to GMC: a. 60 mice [15 males and 15 females (mutants) and 15 males and 15 females (wildtype); the wildtype animals should be littermates of the mutant animals; the animals have to be sent when they are 7 weeks old and genotyped; the maximum age difference between youngest and oldest is 7 days (a high number of mice is necessary to ensure an optimal screen performance)]: (hereinafter referred to as the “MOUSELINE”) ; The MOUSELINE must have a confirmed genetic modification or defined treat- ment. The mice have to bear the ear marking used in the GMC. The GMC can reject the import of mice that bear a different marking for identification. b. The duly completed request form (see section “requests” on www.mouse- xxxxxx.xx) concerning distinctive features of the MOUSELINE has to be filled in with correct information. The request procedure follows the steps outlined on the GMC website (xxx.xxxxxxxxxxx.xx). c. An overview of the MOUSELINE and its specific mutation, the documentation of the confirmation of the mutation and about the already known and confirmed phenotypes (according to the example provided in section “requests” on xxx.xxxxxxxxxxx.xx); the overview should include a publication list. d. Copies of the three most important publications about the MOUSELINE or gene (if such publications exist); e. In case the experiments are performed on genetically altered lines, a severity assessment for genetically altered lines is needed. f. The GMC holds a general license to run phenotype assessments in mice. How- ever every single project needs a final approval by the responsible authority. The Provider has to support the GMC in notifying the project to the appropriate authorities (outline of the collaboration project referring to animal welfare guidelines including an ethical justification for animal experiments)). If the pro- vider does not support the GMC in applying for the approval, or the project is rejected by the appropriate authorities, the GMC has to retract from the collab- oration and cannot be held liable for expenses the COLLABORATION PARTNER invested in the production of the MOUSELINE. g. A health report according to the FELASA recommendations (see section “re- quests” on xxx.xxxxxxxxxxx.xx); this information is vital for the decision if a MOUSELINE can be imported into the GMC. The health report must not be older than 3 months. At the point in time of import a second health certificate (not older than 3 months) has to be provided. If certain pathogens are found at the point in time of import (e.g. any parasites) according to the second health cer- tificate, GMC can reject the import of the mice or reduce the phenotypic check- up. GMC can also stop further analysis, if such pathogens are found during the testing. h. The GMC imports mice only from facilities that are monitored according to FELASA guidelines (4) GMC will analyse the MOUSELINE in a specific GMC-pipeline as agreed upon in writ- ing. A GMC-pipeline comprises the phenotypic analysis from either a generalized or a hypothesis-driven perspective (see section “research” on xxx.xxxxxxxxxxx.xx for available options). GMC and COLLABORATION PARTNER need to agree on the se- lected pipeline prior to the submission for approval of the project with the appropriate authorities. (5) GMC provides its results in form of a phenotyping data report to the COLLABORATION PARTNER. (6) If in GMC’s opinion a full primary screen is not feasible - for instance because of the MOUSELINE’s condition - , GMC has the right to omit specific screens. In case a spe- cific screen is in the specific research area of the COLLABORATION PARTNER, GMC may exclude this screen from the primary screen. (7) Findings uncovered by the analysis that appear to be of particular scientific interest may at the sole discretion of GMC be subject to a more detailed analysis in a second- ary screen. (8) If the COLLABORATION PARTNER collaborates with third parties to have the MOUSE- LINE tested or if he is or was testing the MOUSELINE himself, he is obligated to inform GMC as soon as possible. This applies during the whole time of testing in the GMC and during the time of the preparation of a common manuscript. This includes all findings and all planned experiments. (9) The GMC shall be entitled to keep a part of the mice’s tails for its own archives and tissue samples for own academic research.

PRINCIPLES OF COLLABORATION. (1) It is necessary that the COLLABORATION PARTNER complies with each of the follow- ing requirements, otherwise GMC a. has at its sole discretion the right to reject MOUSELINE or b. may not to carry out one or more particular tests. GMC may in exceptional cases agree to some changes of the requirements (for in- stance instance the number of mice), if it is informed about and has agreed to it before re- ceiving receiving the mice. If GMC accepts a change in its procedure, the COLLABORATION PARTNER accepts that changes may have an impact on the results. However, GMC shall not be obliged to accept the COLLABORATION PARTNER’s request, but may decide to reject it for internal reasons. (2) If GMC rejects the phenotypic analysis because the COLLABORATION PARTNER did not fulfil one or more of the requirements of section 1 (3), the COLLABORATION PARTNER is obliged to reimburse GMC for all incurred expenses in connection with the intended collaboration. (3) The COLLABORATION PARTNER shall deliver number of mice and the following to GMC: a. composition of the cohorts is usually as follows (standard delivery): 60 mice [15 males and 15 females (mutants) and 15 males and 15 females (wildtype); the wildtype animals should be littermates of the mutant animals; the animals have to be sent when they are 7 weeks old and genotyped; the maximum age difference between youngest and oldest is 7 days (a high number of mice is necessary to ensure an optimal screen performance)]: (hereinafter referred 4) The COLLABORATION PARTNER shall deliver the following to GMC: a. Mouse line: 1) Number of mice and the composition of the cohorts as the “MOUSELINE”agreed on in writing (if deviant from standard delivery as stated above) 2) ; The MOUSELINE must have a confirmed genetic modification or defined treat- ment. treatment. 3) The mice have to bear the ear marking used in the GMC. The GMC can reject the import of mice that bear a different marking for identification. b. The duly completed request form (see section “requests” on www.mouse- xxxxxx.xxxxx.xxxxxxxxxxx.xx) concerning distinctive features of the MOUSELINE has to be filled in with correct information. The request procedure follows the steps outlined on the GMC website (xxx.xxxxxxxxxxx.xx). c. An overview of the MOUSELINE and its specific mutation, the documentation of the confirmation of the mutation and about the already known and confirmed phenotypes (according to the example provided in section “requests” on xxx.xxxxxxxxxxx.xx); the overview should include a publication list. d. Copies of the three most important publications about the MOUSELINE or gene (if such publications exist); e. In case the experiments are performed on genetically altered lines, a severity assessment for genetically altered lines is needed. f. The GMC holds a general license to run phenotype assessments in mice. How- ever However every single project needs a final approval by the responsible authority. The Provider COLLABORATION PARTNER has to support the GMC in notifying the project to the appropriate authorities (outline of the collaboration project referring to animal welfare guidelines including an ethical justification for animal experiments)). If the pro- vider COLLABORATION PARTNER does not support the GMC in applying for the approval, or the project is rejected by the appropriate authorities, the GMC has to retract from the collab- oration collaboration and cannot be held liable for expenses the COLLABORATION PARTNER invested in the production of the MOUSELINE. g. A health report according to the FELASA recommendations (see section “re- questsrequests” on xxx.xxxxxxxxxxx.xx); this information is vital for the decision if a MOUSELINE can be imported into the GMC. The health report must not be older than 3 months. At the point in time of import a second health certificate (not older than 3 months) has to be provided. If certain pathogens are found at the point in time of import (e.g. any parasites) according to the second health cer- tificate, GMC can reject the import of the mice or reduce the phenotypic check- up. GMC can also stop further analysis, if such pathogens are found during the testing. h. The GMC imports mice only from facilities that are monitored according to FELASA guidelines (4) GMC will analyse the MOUSELINE in a specific GMC-pipeline as agreed upon in writ- ing. A GMC-pipeline comprises the phenotypic analysis from either a generalized or a hypothesis-driven perspective (see section “research” on xxx.xxxxxxxxxxx.xx for available options). GMC and COLLABORATION PARTNER need to agree on the se- lected pipeline prior to the submission for approval of the project with the appropriate authorities. (5) GMC provides its results in form of a phenotyping data report to the COLLABORATION PARTNER. (6) If in GMC’s opinion a full primary screen is not feasible - for instance because of the MOUSELINE’s condition - , GMC has the right to omit specific screens. In case a spe- cific screen is in the specific research area of the COLLABORATION PARTNER, GMC may exclude this screen from the primary screen. (7) Findings uncovered by the analysis that appear to be of particular scientific interest may at the sole discretion of GMC be subject to a more detailed analysis in a second- ary screen. (8) If the COLLABORATION PARTNER collaborates with third parties to have the MOUSE- LINE tested or if he is or was testing the MOUSELINE himself, he is obligated to inform GMC as soon as possible. This applies during the whole time of testing in the GMC and during the time of the preparation of a common manuscript. This includes all findings and all planned experiments. (9) The GMC shall be entitled to keep a part of the mice’s tails for its own archives and tissue samples for own academic research.than

PRINCIPLES OF COLLABORATION. (1) It is necessary that the COLLABORATION PARTNER complies with each of the follow- ing fol- lowing requirements, otherwise GMC a. has at its sole discretion the right to reject MOUSELINE or b. may not to carry out one or more particular tests. GMC may in exceptional cases agree to some changes of the requirements (for in- stance the number of mice), if it is informed about and has agreed to it before re- ceiving the mice. If GMC accepts a change in its procedure, the COLLABORATION PARTNER accepts that changes may have an impact on the results. However, GMC shall not be obliged to accept the COLLABORATION PARTNER’s request, but may decide to reject it for internal reasons. (2) If GMC rejects the phenotypic analysis because the COLLABORATION PARTNER did not fulfil fulfill one or more of the requirements of section 1 (3), the COLLABORATION PARTNER is obliged to reimburse GMC for all incurred expenses in connection with the intended collaboration. (3) The COLLABORATION PARTNER shall deliver the following to GMC: a. 60 mice [15 males and 15 females (mutants) and 15 males and 15 females (wildtype); the wildtype animals should be littermates of the mutant animals; the animals have to be sent when they are 7 weeks old and genotyped; the maximum age difference between youngest and oldest is 7 days (a high number num- ber of mice is necessary to ensure an optimal screen performance)]: (- hereinafter referred to as the “MOUSELINE”) ; ” - The MOUSELINE must have a confirmed genetic modification or defined treat- menttreatment. The mice have to bear the ear marking used in the GMC. The GMC can reject the import of mice that bear a different marking for identification. b. The duly completed request form (see section “requests” on www.mouse- xxxxxx.xxxxx.xxxxxxxxxxx.xx) concerning distinctive features of the MOUSELINE has to be filled in with correct information. The request procedure follows the steps outlined on the GMC website (xxx.xxxxxxxxxxx.xx). c. An overview of the MOUSELINE and its specific mutation, the documentation of the confirmation of the mutation and about the already known and confirmed con- firmed phenotypes (according to the example provided in section “requests” on xxx.xxxxxxxxxxx.xx); the overview should include a publication list. d. Copies of the three most important publications about the MOUSELINE or gene (if such publications exist); e. In case the experiments are performed on genetically altered lines, a severity assessment for genetically altered lines is needed. f. The GMC holds a general license to run phenotype assessments in mice. How- ever every single project needs a final approval by the responsible authority. The Provider has to support the GMC in notifying the project to the appropriate authorities (outline of the collaboration project referring to animal welfare guidelines including an ethical justification for animal experiments)). If the pro- vider does not support the GMC in applying for the approval, or the project is rejected by the appropriate authorities, the GMC has to retract from the collab- oration and cannot be held liable for expenses the COLLABORATION PARTNER invested in the production of the MOUSELINE. g. A health report according to the FELASA recommendations (see section “re- quests” on xxx.xxxxxxxxxxx.xx); this information is vital for the decision if a MOUSELINE can be imported into the GMC. The health report must not be older than 3 months. At the point in time of import a second health certificate (not older than 3 months) has to be provided. If certain pathogens are found at the point in time of import (e.g. any parasites) according to the second health cer- tificatecertificate, GMC can reject the import of the mice or reduce the phenotypic check- pheno- typic check-up. GMC can also stop further analysis, if such pathogens are found during the testing. h. f. The GMC imports mice only from facilities that are monitored according to FELASA guidelines (4) GMC will analyse the MOUSELINE in a specific GMC-pipeline as agreed upon in writ- ingprimary screen. A GMC-pipeline comprises the primary screen includes a standardized phenotypic analysis from either a generalized or a hypothesis-driven perspective (see section “research” on xxx.xxxxxxxxxxx.xx for available optionsfurther details). If GMC and COLLABORATION PARTNER need to decide on a different, cus- tomized analysis, a head of GMC and the COLLABORATION PARTNER’s responsible scientist will agree on upon the se- lected pipeline prior to the submission for approval of the project with the appropriate authoritiesspecific procedure in writing. (5) GMC provides its results in form of a phenotyping data report to the COLLABORATION COLLABORA- TION PARTNER. (6) If in GMC’s opinion a full primary screen is not feasible - for instance because of the MOUSELINE’s condition - , GMC has the right to omit specific screens. In case a spe- cific specific screen is in the specific research area of the COLLABORATION PARTNER, GMC may exclude this screen from the primary screen. (7) Findings uncovered by the analysis that appear to be of particular scientific interest may at the sole discretion of GMC be subject to a more detailed analysis in a second- ary sec- ondary screen. (8) If the COLLABORATION PARTNER collaborates with third parties to have the MOUSE- LINE MOUSELINE tested or if he is or was testing the MOUSELINE himself, he is obligated to inform GMC as soon as possible. This applies during the whole time of testing in the GMC and during the time of the preparation of a common manuscript. This includes in- cludes all findings and all planned experiments. (9) The GMC shall be entitled to keep a part of the mice’s tails for its own archives and tissue samples for own academic research.

PRINCIPLES OF COLLABORATION. (1) It is necessary that the COLLABORATION PARTNER complies with each of the follow- ing requirements, otherwise GMC a. has at its sole discretion the right to reject MOUSELINE or b. may not to carry out one or more particular tests. GMC may in exceptional cases agree to some changes of the requirements (for in- stance the number of mice), if it is informed about and has agreed to it before re- ceiving the mice. If GMC accepts a change in its procedure, the COLLABORATION PARTNER accepts that changes may have an impact on the results. However, GMC shall not be obliged to accept the COLLABORATION PARTNER’s request, but may decide to reject it for internal reasons. (2) If GMC rejects the phenotypic analysis because the COLLABORATION PARTNER did not fulfil one or more of the requirements of section 1 (3), the COLLABORATION PARTNER is obliged to reimburse GMC for all incurred expenses in connection with the intended collaboration. (3) The COLLABORATION PARTNER shall deliver the following to GMC: a. 60 mice [15 males and 15 females (mutants) and 15 males and 15 females (wildtype); the wildtype animals should be littermates of the mutant animals; the animals have to be sent when they are 7 weeks old and genotyped; the maximum age difference between youngest and oldest is 7 days (a high number of mice is necessary to ensure an optimal screen performance)]: (hereinafter referred to as the “MOUSELINE”) ); The MOUSELINE must have a confirmed genetic modification or defined treat- ment. The mice have to bear the ear marking used in the GMC. The GMC can reject the import of mice that bear a different marking for identification. b. The duly completed request form (see section “requests” on www.mouse- xxxxxx.xx) concerning distinctive features of the MOUSELINE has to be filled in with correct information. The request procedure follows the steps outlined on the GMC website (xxx.xxxxxxxxxxx.xx). c. An overview of the MOUSELINE and its specific mutation, the documentation of the confirmation of the mutation and about the already known and confirmed phenotypes (according to the example provided in section “requests” on xxx.xxxxxxxxxxx.xx); the overview should include a publication list. d. Copies of the three most important publications about the MOUSELINE or gene (if such publications exist); e. In case the experiments are performed on genetically altered lines, a severity assessment for genetically altered lines is needed. f. The GMC holds a general license to run phenotype assessments in mice. How- ever every single project needs a final approval by the responsible authority. The Provider has to support the GMC in notifying the project to the appropriate authorities (outline of the collaboration project referring to animal welfare guidelines including an ethical justification for animal experiments)). If the pro- vider does not support the GMC in applying for the approval, or the project is rejected by the appropriate authorities, the GMC has to retract from the collab- oration and cannot be held liable for expenses the COLLABORATION PARTNER invested in the production of the MOUSELINE. g. . A health report according to the FELASA recommendations (see section “re- questsrequests” on xxx.xxxxxxxxxxx.xx); this information is vital for the decision if a MOUSELINE can be imported into the GMC. The health report must not be older than 3 months. At the point in time of import a second health certificate (not older than 3 months) has to be provided. If certain pathogens are found at the point in time of import (e.g. any parasites) according to the second health cer- tificatecertificate, GMC can reject the import of the mice or reduce the phenotypic check- check-up. GMC can also stop further analysisanal- ysis, if such pathogens are found during the testing. h. g. The GMC imports mice only from facilities that are monitored according to FELASA guidelines (4) GMC will analyse the MOUSELINE in a specific GMC-pipeline as agreed upon in writ- ingprimary screen. A GMC-pipeline comprises the primary screen includes a standardized phenotypic analysis from either a generalized or a hypothesis-driven perspective (see section “research” on xxx.xxxxxxxxxxx.xx for available optionsfurther details). If GMC and COLLABORATION PARTNER need to decide on a different, cus- tomized analysis, a head of GMC and the COLLABORATION PARTNER’s responsible scientist will agree on upon the se- lected pipeline prior to the submission for approval of the project with the appropriate authoritiesspecific procedure in writing. (5) GMC provides its results in form of a phenotyping data report to the COLLABORATION PARTNER. (6) If in GMC’s opinion a full primary screen is not feasible - for instance because of the MOUSELINE’s condition - , GMC has the right to omit specific screens. In case a spe- cific screen is in the specific research area of the COLLABORATION PARTNER, GMC may exclude this screen from the primary screen. (7) Findings uncovered by the analysis that appear to be of particular scientific interest may at the sole discretion of GMC be subject to a more detailed analysis in a second- ary screen. (8) If the COLLABORATION PARTNER collaborates with third parties to have the MOUSE- LINE tested or if he is or was testing the MOUSELINE himself, he is obligated to inform GMC as soon as possible. This applies during the whole time of testing in the GMC and during the time of the preparation of a common manuscript. This includes all findings and all planned experiments. (9) The GMC shall be entitled to keep a part of the mice’s tails for its own archives and tissue samples for own academic research.